Pharmacogenomics and Drug-Drug Interaction between Amiodarone and Metoprolol

A wide range of pharmaceutical medications have been employed to facilitate the blockage of the neurohumoral system that is implicated in the pathogenesis of congestive heart failure (CHF). An often-used antiarrhythmic medication is amiodarone. Treatment for persistent ventricular tachycardia, ventricular fibrillation, and class III atrial fibrillation are indicated. There is curiosity about metoprolol, which is a selective β1-adrenergic receptor blocker. Myocardial infarction, atrial fibrillation/edema, Heart failure (HF), and hypertension are among the conditions for which the FDA has approved treatments. Among the most common reasons for adverse drug reaction (ADR) is drug exposure, and we find that polypharmacy contributes to the higher prevalence of this syndrome among the elderly. Drug interactions involving amiodarone have been documented. mostly blocks CYP2C8 and CYP3A4, with CYP1A2, CYP2C19, and CYP2D6 being slightly blocked as well. The finding that using amiodarone was linked to greater amounts of α-OH-metoprolol was unexpected. The existing literature indicates that the concentration of α-OH-metoprolol will likely decrease with moderate and strong CYP2D6 inhibitors. Cardiovascular Pharmacogenomics focuses on the development and selection of cardiovascular drugs to increase therapeutic efficacy and reduce toxicity. The purpose of this article is to investigate the pharmacogenetic and drug-drug interactions between amiodarone and metoprolol and their side effects.